Genetic Engineering News Reports Companies Capitalizing on Gene Delivery Product Opportunities
Posted on: Tuesday, 16 May 2006, 18:08 CDT
Delivering DNA into cells is one of the most rapidly developing areas of biotechnology and gene therapy, reports Genetic Engineering News (GEN). Cell delivery of DNA is also proving to be a powerful research tool for deciphering gene structure, function, and regulation, according to the May 15 issue of GEN (www.genengnews.com).
"Nonviral methods for gene delivery are particularly promising right now," says John Sterling, Editor-in-Chief of GEN. "However, obstacles remain and these include keeping the cells viable by reducing the toxicity and severity of chemical or electrical exposure. Enhancing efficiency and reproducibility of DNA uptake to drive high-level expression also remains a key challenge."
A number of companies view this arena as a prime business opportunity and have developed products for nonviral methods of DNA delivery. While scientists may transfect a variety of cell lines, this process often requires individual optimization. ATCC and nonviral gene transfer specialists at amaxa joined forces with the goal of streamlining the process. Using its Nucleofector(R) technology on cell lines supplied by ATCC, amaxa is creating and optimizing transfection protocols.
Bio-Rad Laboratories (AMEX:BIO) offers both transfection reagents and electroporation technology. For example, TransFectin(TM) is composed of a cationic lipid and a colipid called DOPE (1,2-dioleoylphosphatidylethanolamine). Eppendorf markets its Multiporator(R) for the transfection of animal and human cell lines, embryonic stem cells, primary cells, plant protoplasts, bacteria, and yeasts.
Invitrogen (NASDAQ:IVGN) offers transfection reagents based on its cationic lipid formulations. The company's flagship product, Lipofectamine(TM) 2000, provides an easy protocol that works efficiently for plasmids and RNAi transfections, according to Henry Chiou, Ph.D., research manager for transfection.
Other companies covered in the GEN article include Mirus, EMD Biosciences, Qiagen (NASDAQ:QGEN), Roche Applied Science (NYSE:RHHBY), Stratagene (NASDAQ:STGN), and Thermo Electron (NYSE:TMO).
For a copy of the May 15 issue, please call 914-740-2122, or email: ebicovny@liebertpub.com.
Genetic Engineering News, which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read and influential worldwide biotechnology news magazine. The publication was recently redesigned to include sections on OMICS, Drug Discovery, Bioprocessing, Translational Medicine, and Biobusiness.
Source: Business Wire
Related Articles
- Improvement Of Liver Stem Cell Engraftment By Protein Delivery
- Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer After First-Line Chemotherapy
- Living Cell Technologies Confirms Insulin Delivery From Implants in Diabetes Clinical Trial
- Cell Phone Spending Surpasses Land Lines
- Gene Logic Identifies Gene Expression Patterns Associated With Multiple Sclerosis in Blood Cells
- Cheek cells' DNA points to lung cancer risk
- Twenty-Somethings More Comfortable With Cell Phones Instead of Land-Lines
- Cell Phone Subscribers Outnumber Land Lines
- New Study Finds How Cells with Damaged DNA Alert the Immune System
- Antiinflammatory Effect of Locally Synthetized scFv-CH2CH3 Anti-C5 Induced By Transfection of Specific Gene
 |
 |
User Comments (0)
RSS Feeds